Portola Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Host Conference Call on Monday, November 9

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2015 (GLOBE NEWSWIRE) — Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced that it will host a webcast and conference call to discuss the Company’s financial results for the quarter ended September 30, 2015, and provide a general business overview on Monday, November 9, 2015 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

Conference Call Details

To access the live conference call, please dial (844) 452-6828 from the U.S. and Canada or +1(765) 507-2588 internationally, and use the passcode 62894229. Please dial in 10 minutes prior to the start of the call.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company’s website at http://investors.portola.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. A replay of the webcast will be available on the Company’s website for 30 days following the live event.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. These programs include betrixaban, an oral, once-daily Factor Xa inhibitor being evaluated in the APEX Phase 3 study for prophylaxis of venous thromboembolism; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola’s partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.

CONTACT: Investor Contact:
Ana Kapor
Portola Pharmaceuticals                                                 
ir@portola.com

Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com  

Left Menu Icon
Right Menu Icon